Pharmaceutical Executive-12-06-2006

Pharmaceutical Executive

Let Bygones Be Bygones

December 06, 2006

0

0

Pfizer, Novartis--and even Merck--are putting the past behind them, and moving forward with COX-2 innovation.

Pure Diversification

December 06, 2006

0

0

Possible sale of medical nutrition unit would not mark change in business model for the diversified drug maker.

The Ripple Effect

December 06, 2006

0

0

Pfizer's torcetrapib blow shifts cost-cutting measures into overdrive, causing all of industry to reevaluate staffing, marketing spend, and the viability of a potential cardiovascular breakthrough.